Flare Therapeutics Inc., a clinical-stage biotechnology company, has appointed Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately.   Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company’s Board of Director...